A universal pretargeting system for cancer detection and therapy using bispecific antibody

Cancer Research

Volumn 63, Issue 2, 2003, Pages 354-363

  Sharkey, Robert M ^a   McBride, William J ^b   Karacay, Habibe ^a   Chang, Ken ^b,c   Griffiths, Gary L ^b   Hansen, Hans J ^b   Goldenberg, David M ^a,b,c  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b IMMUNOMEDICS INC   (United States)

^c IBC Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; GLYCINE; HISTAMINE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMP 24; IMP 243; IMP 245; INDIUM; LUTETIUM; PEPTIDE; SUCCINIC ACID; TECHNETIUM 99M; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER DIAGNOSIS; CANCER THERAPY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; FEMALE; HUMANS; IMMUNOCONJUGATES; MICE; MICE, NUDE; OLIGOPEPTIDES; RADIOIMMUNOTHERAPY; RADIOISOTOPES; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037439925     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Chang, C-H., Sharkey, R. M., Rossi, E. A., Karacay, H. McBride, W., Hansen, H. J., Chatal, J-F., Barbet, J., and Goldenberg, D. M. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol. Cancer Ther., 1: 553-563, 2002.
2. Goodwin, D. A., and Meares, C. F. Pretargeted peptide imaging and therapy. Cancer Biother. Radiopharm., 14: 145-152, 1999.
3. Yuan, F., Baxter, L. T., and Jain, R. K. Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res., 51: 3119-3130, 1991.
4. Hnatowich, D. J., Virzi, F., and Rusckowski, M. Investigations of avidin and biotin for imaging applications. J. Nucl. Med, 28: 1294-1302, 1987.
5. Paganelli, G., Riva, P., Deleide, G., Clivio, A., Chiolerio, F., Scassellati, G. A., Malcovati, M., and Siccardi, A. G. In vivo labeling of biotinylated monoclonal antibodies by radioactive avidin: a strategy to increase tumor radiolocalization. Int. J. Cancer, 2(Suppl.): 121-125, 1988.
6. Axworthy, D. B., Reno, J. M., Hylarides, M. D., Mallett, R. W., Theodore, L. J., Gustavson, L. M., Su, F., Hobson, L. J., Beaumier, P. L., and Fritzberg, A. R. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. USA, 97: 1802-1807, 2000.
7. Reardan, D. T., Meares, C. F., Goodwin, D. A., McTigue, M., David, G. S., Stone, M. R., Leung, J. P., Bartholomew, R. M., and Frincke, J. M. Antibodies to metal chelates. Nature (Lond.), 316: 265-268, 1985.
8. Goodwin, D. A., Meares, C. F., McCall, M. J., McTigue, M., and Chaovapong, W. Pre-targeted immunoscintigraphy of murine tumor with indium-111-labeled bifunctional haptens. J. Nucl. Med., 29: 226-234, 1988.
9. Le Doussal, J-M., Martin, M., Gautherot, E., Delaage, M., and Barbet. J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: Enhanced divalent hapten affinity for cell bound antibody conjugates. J. Nucl. Med., 30: 1358-1366, 1989.
10. Goodwin, D. A., Meares, C. F., McTigue, M., Chaovapong, W., Diamanti, C. I., Ransone, C. H., and McCall, M. J. Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake. J. Nucl. Med., 33: 2006-2013, 1992.
11. Karacay, H., Sharkey, R. M., McBride, W. J., Griffiths, G. L., Qu, Z., Chang, K., Hansen, H. J., and Goldenberg, D. M. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen. Bioconj. Chem., 13: 1054-1070, 2002.
12. Boerman, O. C., Kranenborg, M. H. G. C., Oosterwijk, E., Griffiths, G. L., McBride. W. J., Oyen, W. J., de Weijert, M., Oosterwijk, J., Hansen, H. J., and Corstens, F. H. M. Pretargeting of renal cell carcinoma: Improved tumor targeting with a bivalent chelate. Cancer Res., 59: 4400-4405, 1999.
13. Le Doussal, J-M., Gruaz-Guyon, A., Martin, M., Gautherot, E., Delaage, M., and Barbet, J. Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res., 50: 3445-3452, 1990.
14. Feng, X., Pak, R. H., Kroger, L. A., Moran, J. K., DeNardo, D. G., Meares, C. F., DeNardo, G. L., and DeNardo, S. J. New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor. Hybridoma, 17: 125-132, 1998.
15. Janevik-Ivanovska, E., Gautherot, E., Hillairet deBoisferon, M., Cohen, M., Milhaud, G., Tartar, A., Rostene, W., Barbet, J., and Gruaz-Guyon, A. Bivalent hapten-bearing peptides designed for ioidine-131 pretargeted radioimmunotherapy. Bioconj. Chem., 8: 526-533, 1997.
16. Hosono, M., Hosono, M. N., Kraeber-Bodéré, F., Devys, A., Thédrez, P., Faivre-Chauvet, A., Gautherot, E., Barbet, J., and Chatal, J-F. Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten. J. Nucl. Med., 40: 1216-1221. 1999.
17. Sharkey, R. M., Juweid, M., Shevitz, J., Behr, T., Dunn, R., Swayne, L. C., Wong, G. Y., Blumenthal, R. D., Griffiths, G. L., Siegel, J. A., Leung, S., Hansen, H. J., and Goldenberg, D. M. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res., 55: 5935s-5945s, 1995.
18. Nocera, M. A., Shochat, D., Primus, F. J., Krupey, J., Jespersen, D., and Goldenberg, D. M. Representation of epitopes on colon-specific antigen-p (CSAp) defined by monoclonal antibodies. J. Natl. Cancer Inst., 79: 943-948, 1987.
19. Gold, D. V., Nocera, M. A., Stephens, R., and Goldenberg, D. M. Murine monoclonal antibodies to colon-specific antigen-p (CSAp). Cancer Res., 50: 6405-6409, 1990.
20. Sharkey, R. M., Gold, D. V., Aninipot, R., Vagg, R., Ballance, C., Newman, E., Ostella, F., Hansen, H. J., and Goldenberg, D. M. Comparison of tumor targeting in nude mice murine monoclonal antibodies directed against different human colorectal cancer antigens. Cancer Res., 50: 828s-834s, 1990.
21. Greenwood, F. C., and Hunter, W. M. The preparation of I-131 labeled human growth hormone of high specific radioactivity. Biochem. J., 89: 114-123, 1963.
22. Griffiths, G. L., Goldenberg, D. M., Diril, H., and Hansen, H. J. Technetium-99m, rhenium-186 and rhenium-188 direct-labeled antibodies. Cancer (Phila.), 73(Suppl.): 761-768, 1994.
23. 888Re-labeled peptide. Bioconjug. Chem., 11: 842-854, 2000.
24. Goldenberg, D. M., and Hansen, H. J. Carcinoembryonic antigen present in human colonic neoplasms serially propagated in hamsters. Science (Wash. DC), 175: 1117-1118, 1972.
25. Sharkey, R. M., Motta-Hennessy, C., Pawlyk, D., Siegel, J. A., and Goldenberg, D. M. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res., 50: 2330-2336, 1990.
26. Le Doussal, J-M., Barbet, J., and Delaage. Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: Theoretical, experimental, and clinical results. Int. J. Cancer, 7(Suppl.): 58-62, 1992.
27. Gautherot, E., Le Doussal, J-M., Bouhou, J., Manetti, C., Martin, M., Rouvier, E., and Barbet, J. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. J. Nucl. Med., 39: 1937-1943, 1998.
28. 131I-labeled bivalent hapten. J. Nucl. Med., 41: 480-487, 2000.
29. Goodwin, D. A., Chaovapong, W., Meares, C. F., and McCall, M. J. New monoclonal antibodies for targeting radiopharmaceuticals. J. Nucl. Med., 28: 561, 1987.
30. Morel, A., Darmon, M., and Delaage, M. Recognition of imidazole and histamine derivatives by monoclonal antibodies. Mol. Immunol., 27: 995-1000, 1990.
31. 188Re-labeled bivalent hapten: Biodistribution and dosimetry studies. J. Nucl. Med., 42: 146-153, 2001.
32. Wiseman, G. A., White, C. A., Sparks, R. B., Erwin, W. D., Podoloff, D. A., Lamonica, D., Bartlett, N. L., Parker, J. A., Dunn, W. L., Spies, S. M., Belanger, R., Witzig, T. E., and Leigh, B. R. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit. Rev. Oncol. Hematol., 39: 181-194, 2001.
33. Meredith, R. F., Alvarez, R. D., Partridge, E. E., Khazaeli, M. B., Lin, C. Y., Macey, D. J., Austin, J. M., Jr., Kilgore, L. C., Grizzle, W. E., Schlom, J., and LoBuglio, A. F. Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study. Cancer Biother. Radiopharm., 16: 305-315, 2001.
34. Knox, S. J., Goris, M. L., Tempero, M., Weiden, P. L., Gentner, L., Breitz, H., Adams, G. P., Axworthy, D., Gaffigan, S., Bryan, K., Fisher, D. R., Colcher, D., Horak, I. D., and Weiner, L. M. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin. Cancer Res., 6: 406-414, 2000.
35. 131I-labeled hapten in pretargeted radioimmunotherapy patients. J. Nucl. Med., 43: 159p (abstract 579), 2002.
36. 99mTc-labeled peptides. J. Nucl. Med., 41: 177-182, 2000.
37. 99mTc antibody fragment (CEA-Scan™; arcitumomab) in patients undergoing surgery for carcinoma of the colon and rectum. J. Clin. Oncol., 14: 2295-2305, 1996.
38. D. M. Goldenberg, H. A. Nabi, C. L. Sullivan, A. Serafini, D. Seldin, B. Barron, L. Lamki, B. Line, and W. A. Wegener: Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma. Cancer (Phila.), 89: 104-115, 2000.
39. v6/antigallium chelate antibodies. J. Nucl. Med., 39: 1769-1776, 1998.
40. Schuhmacher, J., Klivényi, G., Kaul, S., Henze, M., Matys, R., Hauser, H., and Clorius, J. Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC-1/anti Ga chelate antibodies and immunoscintigraphy with PET. Nucl. Med. Biol., 28: 821-828, 2001.
41. Sharkey, R. M., Goldenberg, D. M., Vagg, R., Pawlyk, D., Wong, G. Y., Siegel, J. A., Murthy, S., Levine, G. M., Izon, D., Gascon, P., Burger, K., Swayne, L. C., and Hansen, H. J. Phase I clinical evaluation of a new murine monoclonal antibody (Mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas. Cancer (Phila.), 73: 864-877. 1994.
42. Sharkey, R. M., Rossi, E., Karacay, H., McBride, W., Chang, K., Zang, L., Qu, T., Griffiths, G. L., Hansen, H. J., and Goldenberg, D. M. A novel, recombinant, bispecific antibody pretargeting system for cancer radioimmunotherapy. Clin. Cancer Res., 7: 3786s, 2001.